1 2

# Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance

3

4 James Hollister<sup>1\*</sup>, Cynthia Porter<sup>1</sup>, Ryan Sprissler<sup>2</sup>, Shawn C Beitel<sup>1</sup>, James K. Romine<sup>1</sup>, Jennifer

- 5 L. Uhrlaub<sup>4</sup>, Lauren Grant<sup>3</sup>, Young M. Yoo<sup>3</sup>, Ashley Fowlkes<sup>3</sup>, Amadea Britton<sup>5</sup>, Lauren E.W.
- 6 Olsho<sup>6</sup>, Gabriella Newes-Adeyi<sup>6</sup>, Sammantha Fuller<sup>6</sup>, Pearl Q. Zheng<sup>6</sup>, Manjusha Gaglani<sup>7,8</sup>,
- 7 Spencer Rose<sup>7</sup>, Kayan Dunnigan<sup>7</sup>, Allison L. Naleway<sup>9</sup>, Lisa Gwynn<sup>10</sup>, Alberto Caban-
- 8 Martinez<sup>10</sup>, Natasha Schaefer Solle<sup>10</sup>, Harmony L. Tyner<sup>11</sup>, Andrew L. Philips<sup>12</sup>, Kurt T
- 9 Hegmann<sup>12</sup>, Sarang Yoon<sup>12</sup>, Karen Lutrick<sup>13</sup>, Jefferey L. Burgess<sup>1</sup>, Katherine D. Ellingson<sup>1</sup>
- 10
- 11 Author affiliations
- <sup>1</sup> Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona
- <sup>13</sup> <sup>2</sup> University of Arizona Genetics Core Center for Applied Genetics and Genomic Medicine,
- 14 University of Arizona, Tucson, Arizona
- <sup>3</sup> Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for
- 16 Disease Control and Prevention, Atlanta, Georgia<sup>4</sup> Immunobiology, College of Medicine –
- 17 Tucson, University of Arizona, University of Arizona Health Sciences, Tucson, Arizona
- 18 <sup>5</sup> Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and
- 19 Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
- 20 <sup>6</sup> Abt Associates, Rockville, Maryland
- <sup>7</sup> Baylor Scott & White Health, Temple, Texas
- 22 <sup>8</sup> Texas A&M University College of Medicine, Temple, Texas
- 23 <sup>9</sup> Kaiser Permanente Center for Health Research, Portland, Oregon
- 24 <sup>10</sup> Leonard M. Miller School of Medicine, University of Miami, Miami, Florida
- <sup>25</sup> <sup>11</sup> St. Luke's Regional Health Care System, Duluth, Minnesota
- <sup>26</sup> <sup>12</sup> Rocky Mountain Center for Occupational and Environmental Health, Department of Family
- 27 and Preventive Medicine, University of Utah Health, Salt Lake City, Utah
- <sup>13</sup> Family and Community Medicine, College of Medicine Tucson, University of Arizona
- 29 Health Sciences, Tucson, Arizona
- 30
- 31
- 32 \* Corresponding author
- 33 E-mail: jameshollister@arizona.edu

34

- 35
- 36
- 37
- 38
- 39
- 40 41
- 42
- 43
- 44
- 44 45
- 46

### 47 Abstract

48 The extent to which semi-quantitative antibody levels confer protection against SARS-49 CoV-2 infection in populations with heterogenous immune histories is unclear. Two nested case-50 control studies were designed within the multisite HEROES/RECOVER prospective cohort of 51 frontline workers to study the relationship between antibody levels and protection against first-52 time post-vaccination infection and reinfection with SARS-CoV-2 from December 2021 to 53 January 2023. All participants submitted weekly nasal swabs for rRT-PCR testing and blood 54 samples quarterly and following infection or vaccination. Cases of first-time post-vaccination 55 infection following a third dose of monovalent (origin strain WA-1) mRNA vaccine (n=613) and 56 reinfection (n=350) were 1:1 matched to controls based on timing of blood draw and other 57 potential confounders. Conditional logistic regression models were fit to estimate infection risk 58 reductions associated with 3-fold increases in end titers for receptor binding domain (RBD). In 59 first-time post-vaccination and reinfection study samples, most were female (67%, 57%), non-60 Hispanic (82%, 68%), and without chronic conditions (65%, 65%). The odds of first-time post-61 vaccination infection were reduced by 21% (aOR=0.79, 95% CI=[0.66-0.96]) for each 3-fold 62 increase in RBD end titers. The odds of reinfection associated with a 3-fold increase in RBD end 63 titers were reduced by 23% (aOR=0.77, 95% CI=[0.65-0.92] for unvaccinated individuals and 58% (aOR=0.42, 95% CI=0.22-0.84) for individuals with three mRNA vaccine doses following 64 65 their first infection. Frontline workers with higher antibody levels following a third dose of 66 mRNA COVID-19 vaccine were at reduced risk of SARS-CoV-2 during Omicron predominance. 67 Among those with previous infections, the point estimates of risk reduction associated with 68 antibody levels was greater for those with three vaccine doses compared to those who were 69 unvaccinated.

### 70 Introduction

71 The Coronavirus Disease 2019 (COVID-19) pandemic has transitioned from a phase 72 defined by acute morbidity and mortality in immunologically naïve populations to one defined 73 by post-vaccination infections and reinfections in populations with various combinations of 74 infection- and vaccine-induced immunity. Emergence of highly transmissible Omicron 75 subvariants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerated 76 transmission despite high levels of population immunity to the prior strains and subvariants [1]. 77 The first vaccine trials established that higher post-vaccine antibody levels were correlated with 78 increased protection against SARS-CoV-2 infection [2]. Other cohort studies have demonstrated 79 variable response to the vaccines based on individual history of infection [3-5]. It is critical to 80 understand the relationship between antibody levels and protection against Omicron post-81 vaccination infections and reinfections in populations with heterogenous infection and 82 vaccination histories [6].

83 Conceptually, establishing and validating specific antibody levels that correlate with 84 protection against SARS-CoV-2 infection could result in biomarkers that are reliably predictive 85 of vaccine effectiveness [7]. For influenza, hemagglutination inhibition (HI) assay titers have 86 proven useful in comparing different vaccines, with HI end titers of 1:40 generally accepted to be 87 associated with a 50% reduction in risk of influenza [8, 9]. However, establishing SARS-CoV-2 88 antibody correlates of protection is complicated by the rapid emergence of variants and 89 subvariants, differences in assays used to quantify antibody levels, and differential waning of 90 antibody levels over time relative to immune conferring events [3, 10]. Nonetheless, calls for 91 SARS-CoV-2 correlates of protection persist as questions remain regarding the durability of

92 immunity over time given the evolution of subvariants capable of evading acquired immune93 responses [11, 12].

94 Uncertainties also remain in determining optimal timing for future COVID-19 vaccine 95 doses [13]. This report examined the relationship between humoral antibody levels and the risks 96 of 1) first-time post-vaccination infection following a third dose of an origin strain WA-1 97 monovalent mRNA vaccine; and 2) reinfection among individuals with one previous infection 98 stratified by vaccination status at the time of reinfection (i.e., unvaccinated or had received two 99 to three doses of mRNA vaccine) during early Omicron predominance.

### 100 Materials and methods

#### 101 Study design

102 Two nested case-control studies were designed within a prospective cohort of frontline 103 workers from eight locations in the United States (US) to study the relationship between 104 antibody levels and SARS-CoV-2 infections during early Omicron predominance (defined here 105 as December 2021 through September 2022). The first study defined cases as those with a first-106 time SARS-CoV-2 post-vaccination infection following a third dose of COVID-19 origin strain 107 WA-1 monovalent mRNA vaccine. The second defined cases as those infected with SARS-CoV-108 2 after one previous infection; at the time of reinfection, cases were either unvaccinated or had 109 received two to three doses of COVID-19 origin strain WA-1 monovalent mRNA vaccine.

#### 110 **Participants**

Beginning on July 27, 2020, frontline workers were followed in prospective cohorts
through the Arizona Healthcare, Emergency Response, and Other Essential workers Study
(HEROES) and the Research on the Epidemiology of SARS-CoV-2 in Essential Response

114 Personnel (RECOVER) sites in Arizona, Florida, Minnesota, Oregon, Texas, and Utah [14, 15]. 115 Briefly, eligible participants included adults who worked at least 20 hours per week in 116 occupations that required frequent direct contact with non-household members (i.e., healthcare 117 workers, first responders, and other essential workers). Recruitment ended on April 15, 2023. 118 Upon enrollment, participants completed a survey to collect baseline information about 119 characteristics related to sociodemographic, occupation, health status, health-related behaviors, 120 and prior SARS-CoV-2 infection. COVID-19 vaccination information was self-reported through 121 surveys and validated through state vaccine registries or medical records. Additional surveys 122 were completed upon infection, and self-reported information on mask use and exposures was 123 collected monthly. 124 Each week and at onset of symptoms, participants provided a mid-turbinate nasal 125 specimen that was tested at the Marshfield Clinic Laboratory (Marshfield, WI) via real time 126 reverse transcription-polymerase chain reaction (rRT-PCR) for the presence of SARS-CoV-2. 127 Additionally, participants were asked to submit blood samples at three frequencies: (1) upon 128 enrollment, (2) quarterly, and (3) 28 days after any immunity-conferring event (SARS CoV-2 129 infection or COVID-19 vaccination). All study protocols were reviewed and approved by each 130 site's Institutional Review Boards. Study participants provided informed written consent for all 131 study activities.

### 132 Study inclusion criteria and case definition

For the first analytic study sample, cases of first-time post-vaccination infections were defined as individuals with an incident SARS-CoV-2 infection occurring at least 14 days after a third dose \_origin strain WA-1 monovalent Pfizer-BioNTech COVID-19 mRNA vaccine, Moderna COVID-19 mRNA-1273 or a combination of the two vaccines among individuals with

137 no history of previous infection. Infection history prior to enrollment was ascertained via self-138 report upon study enrollment and confirmed with a qualitative result from the baseline blood 139 draw, if available, among only those unvaccinated at the time of enrollment by examining S2 and 140 RBD (S3 and S4 Figs). If a participant was vaccinated at the time of their baseline blood draw, 141 then we solely relied on self-reported data for pre-study infection history. Although nucleocapsid 142 (N) titers were available for all participants with a baseline blood collection, they were unable to 143 be used to detect prior SARS-CoV-2 infections due to low specificity and sensitivity. Variant of 144 infection was confirmed by whole-genome sequencing for eligible specimens, or estimated by 145 using the state-specific predominant variant at the time of infection according to Centers for 146 Disease Control and Prevention data [16]. To be included in this study, participants had to have 147 submitted a nasal specimen at least 80% of weeks and collected blood draws per the study 148 protocol during the study period with no evidence of SARS-CoV-2 infection at the time of the 149 blood draw following their third dose of vaccine. Cases were defined as participants who tested 150 positive for SARS-CoV-2 after the blood draw and prior to any additional vaccine dose (Fig 1). 151 Third vaccine doses occurred from June 2021 to April 2022, blood draws occurred from June 152 2021 to August 2022, and Omicron infections occurred from December 2021 and September 153 2022.

154

Fig 1. Flowcharts showing inclusion and exclusion criteria for nested case-control studies
within the HEROES/RECOVER cohort of frontline workers: 613 cases of first-time postvaccination infection following a third dose of COVID-19 origin strain WA-1 monovalent
mRNA vaccine were matched 1:1 to controls based on site and time between vaccination
and blood draw.

160

161	Within the second analytic study sample, reinfection cases were defined as one of three
162	groups (1) participants who had a previous infection but were unvaccinated, (2); participants
163	with a previous infection followed by completion of two doses of a monovalent COVID-19
164	mRNA vaccine (primary series only); or (3) participants with a previous infection followed by
165	three doses of a monovalent COVID-19 mRNA vaccine (primary series and a third monovalent
166	dose). Reinfections were defined as Omicron infections occurring at least 90 days after a
167	previous Omicron SARS-CoV-2 infection or at least 45 days after a previous infection of a
168	distinct variant (e.g., WA-1 vs. Delta vs. Omicron). Variant of first infection and reinfection was
169	confirmed by either whole-genome sequencing for eligible specimens, or estimated by using the
170	state-specific predominant variant at the time of infection according to Centers for Disease
171	Control and Prevention data [16]. Those receiving a Janssen Ad26.COV2.S COVID-19 vaccine
172	and those with only one mRNA vaccination were ineligible, thus included cases had none, two,
173	or three immunizations. Participants were eligible for the reinfection study sample set if they: (1)
174	had either reported testing positive for SARS-CoV-2 prior to enrollment or tested positive by
175	rRT-PCR during the study period prior to COVID-19 vaccination, and (2) had a blood draw at
176	any time after their last immune conferring event (first infection for unvaccinated participants or
177	last vaccine dose for vaccinated participants). For this group, a case was defined as a participant
178	with a confirmed reinfection after the blood draw (Fig 2). Initial infections occurred from March
179	2020 to August 2022, blood draws occurred from August 2020 to November 2022, and
180	reinfections occurred from December 2021 to January 2023.
181	

182	Fig 2. Flowcharts showing inclusion and exclusion criteria for nested case-control studies
183	within the HEROES/RECOVER cohort of frontline workers: 350 cases of reinfection were
184	matched 1:1 to controls based on site, vaccination status, variant of first infection, and time
185	between immune conferring event (either vaccine or infection) and blood draw.

186

#### 187 Matching

188 The final analytic samples were created by matching eligible cases to controls in a 1:1 189 ratio. Matched controls for the first-time post-vaccination cases included individuals with no 190 history of infection who were matched by study site and days between the third origin strain 191 WA-1 monovalent COVID-19 mRNA vaccine and blood draw. Matched controls for reinfection 192 cases included individuals with a history of one infection who were matched to cases by: study 193 site, variant of first infection (origin strain WA-1, Delta, or Omicron), vaccination status at the 194 time of blood draw, and days between last immune conferring event (first infection for 195 unvaccinated participants or last A vaccine dose for vaccinated participants) and blood draw. For 196 both groups, time windows were used to match days between immune conferring events and 197 blood draws rather than exact matches. For blood samples that were collected less than 150 days 198 since the last immune conferring events, time difference windows of 3, 7, 14, and 21 days were 199 each attempted to find the highest match quality. For blood samples collected at least 150 days 200 since the last immune conferring events, no strict time differences were used.

201 Semi-quantitative serological measures

All sera from all sites were sent to the University of Arizona Genetics Core laboratory for testing using a locally-developed and validated semi-quantitative enzyme-linked immunosorbent assay (ELISA) to measure antibody binding to the receptor binding domain (RBD) and S2

205	subunit domain (S2) of the SARS-CoV-2 Washington-1 spike protein, as previously described
206	[17]. Five 3-fold dilutions of immune sera were made starting at a 1:60 dilution and ending at
207	1:4860. End titer values represent the first dilution in which an immune response was no longer
208	detected. Those with immune response still detected at the final dilution were imputed to 1:9720.
209	Additionally, RBD and S2 antibody levels were measured as the area under the serial dilution
210	curve (AUC). This continuous measurement represents a weighted sum of the optical density
211	value at each dilution. Both end titer and AUC measurements of RBD and S2 were included in
212	the present analysis.

#### 213 Statistical analysis

214 Analyses were conducted using SAS Studio v9.4, GraphPad Prism v9.5.1, and R v4.2.0. 215 Demographic information and measured antibody response for cases and controls was compared 216 using paired t tests and univariate conditional logistic regression for continuous and categorical 217 variables. The outcomes of first-time post-vaccination infection and reinfection with Omicron 218 were modeled using conditional logistic regression to assess the unadjusted and adjusted effects 219 of RBD and S2 humoral antibody levels. Adjusted odds ratios were calculated with models 220 including the following variables that were selected a priori as putative confounders: gender, age 221 (18-49 or over 50 years), presence of at least one chronic condition (i.e. asthma, chronic lung 222 disease, cancer, diabetes, heart disease, hypertension, immunosuppression, kidney disease, liver 223 disease, neurologic or neuromuscular disease or disorder, and autoimmune disease), high 224 exposure to individuals infected with SARS-CoV-2 (above the cohort mean number of weekly 225 hours), high reported mask use in the community (above the cohort mean percentage), and high 226 reported personal protective equipment (PPE) adherence at work (above the cohort mean 227 percentage), where reported PPE adherence at work was defined as the percentage of time in

228 which an individual uses the PPE recommended by their employer when in direct contact with 229 people. For the reinfection study sample, separate models were fit for each category of 230 vaccination status: unvaccinated, 2 doses, and 3 doses of the origin strain WA-1 monovalent 231 COVID-19 mRNA vaccine. In addition, we conducted a likelihood ratio test to assess the 232 interaction term between vaccination status and antibody titer within the reinfection sample. 233 AUC antibody values were standardized by z-scores prior to modeling for ease of 234 interpretation. For end titer data, a log base 3 transformation was used due to the three-fold 235 dilution assay and was treated as a continuous value. Curves displaying the estimated percent 236 reduction in risk were estimated for both first-time post-vaccination infection and reinfection 237 models using an end titer level of 1:60 as the reference. The estimated percent reduction in risk 238 was calculated at each titer level. The 95% confidence interval bounds on the curves were 239 estimated when percent reduction in risk at each titer level was statistically significant at the 0.05 240 alpha level [2, 18]. Using risk reduction curves, we estimated the titer level for a 50% reduction 241 in risk and reported the titer levels used in the ELISA in which the estimate fell between, as is 242 standard in a typical correlates of protection analysis [8, 18, 19].

# 243 **Results**



#### 245 dose of COVID-19 origin strain WA-1 monovalent mRNA vaccine

The incidence of first-time vaccine post-vaccination infections with the Omicron variant following a third dose of origin strain WA-1 monovalent COVID-19 mRNA vaccine was 1.68 per 1000 person-days (830 infections) in the HEROES/RECOVER cohort. In the sample set of 613 first-time post-vaccination cases and 613 matched controls, most participants were female

250	(67%), white and non-Hispanic (82%), healthcare workers (64%), and had no chronic conditions
251	(65%) (Table 1). There was a small but statistically significant difference in days between third
252	vaccination and blood draw (41.4 days for cases and 42.4 days for controls, p=0.003). Compared
253	to cases, controls were slightly older (46y vs. 43y, p<0.001), and had modestly higher reported
254	mask use in the community (61.1% vs. 57.2%) and higher reported PPE adherence at work
255	(81.6% v. 77.0%) (Table 1).
256	
257	Table 1. Demographic and health characteristics for nested case-control samples within the
258	HEROES/RECOVER prospective cohort of frontline workers: the first-time post-
259	vaccination sample was matched by site and days between booster vaccine and blood draw,
260	and the reinfection sample was matched on site, vaccination status, variant of first
261	infection, and days between most recent immune conferring event and blood draw.
262	

	Sample						
	First-time p	ost-vaccination	1 infection				
	Cases	Controls	p-value <sup>a</sup>	Cases	Controls	p-value <sup>a</sup>	
	(n=613)	(n=613)		(n=350)	(n=350)		
Site, n (%)			1.00			1.00	
Tucson, AZ	145 (23.7)	145 (23.7)		123 (35.1)	123 (35.1)		
Phoenix, AZ	73 (11.9)	73 (11.9)		46 (13.1)	46 (13.1)		
Other, AZ	37 (6.0)	37 (6.0)		28 (8.0)	28 (8.0)		
Florida	22 (3.6)	22 (3.6)		50 (14.3)	50 (14.3)		
Minnesota	132 (21.5)	132 (21.5)		30 (8.6)	30 (8.6)		
Oregon	37 (6.0)	37 (6.0)		5 (1.4)	5 (1.4)		
Texas	33 (5.4)	33 (5.4)		22 (6.3)	22 (6.3)		
Utah	134 (21.9)	134 (21.9)		46 (13.1)	46 (13.1)		
Vaccination status <sup>b</sup>			1.00			1.00	
Unvaccinated	0 (0.0)	0 (0.0)		157 (44.9)	157 (44.9)		
2 Doses	0 (0.0)	0 (0.0)		95 (27.1)	95 (27.1)		

3 Doses	613 (100.0)	613 (100.0)		98 (28.0)	98 (28.0)	
Variant of first infection			NA			1.00
Origin strain WA-1	NA	NA		267 (76.3)	267 (76.3)	
Delta	NA	NA		48 (13.7)	48 (13.7)	
Omicron	613 (100)	NA		35 (10.0)	35 (10.0)	
Days from ICE to blood draw, mean (SD) <sup>c</sup>	41.4 (39.8)	42.4 (40.6)	0.0003	113.2 (108.9)	129.3 (136.3)	< 0.001
Age (y), mean (SD)	43.0 (10.0)	46.4 (11.9)	< 0.001	45.6 (11.1)	44.3 (11.6)	0.10
Gender, n (%)			0.60			0.16
Female	415 (67.7)	406 (66.2)		189 (54.0)	208 (59.4)	
Male	197 (32.1)	205 (33.4)		159 (45.4)	142 (40.6)	
Other	1 (0.2)	2 (0.3)		0 (0.0)	0 (0.0)	
Missing	0 (0.0)	0 (0.0)		2 (0.6)	0 (0.0)	
Race/ethnicity, n (%)			0.24			0.41
Non-Hispanic, White	489 (79.8)	512 (83.5)		232 (66.3)	245 (70.0)	
Hispanic	72 (11.7)	52 (8.5)		89 (25.4)	72 (20.6)	
Non-Hispanic, Black	18 (2.9)	19 (3.1)		11 (3.1)	10 (2.9)	
Non-Hispanic, Asian	18 (2.9)	23 (3.8)		3 (0.9)	7 (2.0)	
Other	8 (1.3)	5 (0.8)		4 (1.1)	5 (1.4)	
Missing	8 (1.3)	2 (0.3)		11 (3.1)	11 (3.1)	
Occupation, n (%) <sup>d</sup>			0.06			0.06
Healthcare Worker	376 (61.3)	411 (67.0)		125 (35.7)	145 (41.4)	
First Responder	79 (12.9)	60 (9.8)		117 (33.4)	92 (26.3)	
Other Essential Worker	158 (25.8)	142 (23.2)		108 (30.9)	113 (32.3)	
Chronic conditions, n (%) <sup>e</sup>			0.91			0.24
None	403 (65.7)	397 (64.8)		237 (67.7)	216 (61.7)	
One	114 (18.6)	113 (18.4)		73 (20.9)	74 (21.1)	
Two Or More	93 (15.2)	98 (16.0)		33 (9.4)	44 (12.6)	
Missing	3 (0.5)	5 (0.8)		7 (2.0)	16 (4.6)	
Immunosuppressive medication, n (%) <sup>f</sup>			0.70			0.82
Yes	14 (2.3)	12 (2.0)		11 (3.1)	10 (2.9)	
No	590 (96.2)	592 (96.6)		330 (94.3)	320 (91.4)	
Missing	9 (1.5)	9 (1.5)		9 (2.6)	20 (5.7)	
Days from ICE to infection, mean (SD) <sup>e</sup>	183.0 (80.6)	NA	NA	341.0 (180.6)	NA	NA
Avg weekly hrs. exposed to COVID, mean (SD) <sup>g</sup>	4.8 (9.9)	5.0 (10.4)	0.74	7.0 (12.0)	6.2 (10.5)	0.51
Avg % adherence to PPE rules at work, mean (SD) <sup>h</sup>	77.0 (26.4)	81.6 (24.3)	0.001	58.2 (31.7)	62.3 (32.1)	0.09
Avg % time masked in public, mean (SD)	57.2 (29.1)	61.1 (29.7)	0.01	41.7 (28.7)	47.3 (32.6)	0.02

263	
264	<sup>a</sup> From paired t-test and conditional logistic regression for continuous and categorical variables, respectively.
265	<sup>b</sup> All vaccine doses are monovalent origin strain WA-1 mRNA vaccines.
266	°ICE (immune conferring event) is the third vaccine dose for the first-time post-vaccination infection with Omicron
267	case-control cohort and the 3 dose strata within the reinfection case-control cohort, the second vaccine dose for the 2
268	dose strata within the reinfection case-control cohort, and the initial SARS-CoV-2 infection for the unvaccinated
269	strata within the reinfection case-control cohort.
270	<sup>d</sup> Other essential workers include occupation sectors with potentially high exposures to SARS-CoV-2 such as
271	education, agriculture, public transportation services, waste collection, delivery, utilities, community-based services,
272	childcare, and others
273	°Chronic conditions include asthma, chronic lung disease, cancer, diabetes, heart disease, hypertension,
274	immunosuppression, kidney disease, liver disease, neurologic or neuromuscular disease or disorder, and
275	autoimmune disease.
276	<sup>f</sup> Participants are asked "Are you currently taking prednisone or other ongoing steroid medications (excluding
277	inhaled steroids and one-time injections) or any other medications that may suppress your body's ability to fight
278	infection?".
279	<sup>g</sup> Exposure to individuals infected with SARS-CoV-2.
280	<sup>h</sup> Reported personal protective equipment (PPE) adherence at work was defined as the percentage of time in which an
281	individual uses the PPE recommended by their employer when in direct contact with people
282	
283	For cases, the mean number of days between the third vaccine dose and infection was 183
284	days. Compared to cases, a higher percentage of controls had the maximum end titer values
285	(1:9720) for RBD (65.1% vs. 56.9%,) and S2 (41.1% vs. 32.0%), but the distribution between
286	cases and controls for RBD end titer values was not statistically significant. Controls had
287	significantly higher mean RBD (0.0124 vs. 0.0118) and S2 (0.0102 vs. 0.0097) AUC values
288	compared to cases (Table 2, S1 Fig).
289	

- 290
- 291
- 292 Table 2. Quantitative antibody results, including end titers and area under the curve
- 293 (AUC) calculations for SARS-CoV-2 receptor-binding domain (RBD) and (S2) spike
- 294 protein subunits in nested case-control samples from the HEROES/RECOVER prospective
- 295 **cohort of frontline workers.**
- 296

	Sample						
Variable	First-tin	ne post-vaccinatio	n	Reinfection			
	Cases	Controls	p-value <sup>a</sup>	Cases	Controls	p-value <sup>a</sup>	
	(n=613)	(n=613)		(n=350)	(n=350)		
RBD End Titer, n (%)			0.08			0.003	
1:60	4 (0.7)	3 (0.5)		36 (10.3)	19 (5.4)		
1:180	5 (0.8)	3 (0.5)		31 (8.9)	25 (7.1)		
1:540	14 (2.3)	13 (2.1)		43 (12.3)	38 (10.9)		
1:1620	45 (7.3)	39 (6.4)		55 (15.7)	51 (14.6)		
1:4860	196 (32.0)	156 (25.4)		66 (18.9)	77 (22.0)		
1:9720 <sup>b</sup>	349 (56.9)	399 (65.1)		119 (34.0)	140 (40.0)		
RBD AUC, mean (SD)	0.0118 (0.003)	0.0124 (0.003)	< 0.0001	0.0088 (0.005)	0.0098 (0.005)	0.0002	
S2 End Titer, n (%)			0.002			0.003	
1:60	7 (1.1)	2 (0.3)		9 (2.6)	2 (0.6)		
1:180	8 (1.3)	6 (1.0)		3 (0.9)	4 (1.1)		
1:540	24 (3.9)	21 (3.4)		26 (7.4)	25 (7.1)		
1:1620	120 (19.6)	90 (14.7)		95 (27.1)	64 (18.3)		
1:4860	258 (42.1)	242 (39.5)		95 (27.1)	124 (35.4)		
1:9720 <sup>b</sup>	196 (32.0)	252 (41.1)		122 (34.9)	131 (37.4)		
S2 AUC, mean (SD)	0.0097 (0.003)	0.0102 (0.003)	0.0003	0.0102 (0.004)	0.0110 (0.003)	0.0005	

<sup>298</sup> <sup>a</sup>From paired t-test and conditional logistic regression for continuous and categorical variables, respectively.

<sup>b</sup>Samples where antibody response was still detected at the final dilution were imputed to 1:9720.

300

301 Unadjusted and adjusted conditional logistic regression models for first-time vaccine-302 post-vaccination infection with Omicron infection following a third dose of an origin strain WA-303 1 monovalent COVID-19 mRNA vaccine showed statistically significant protective effects for 304 RBD and S2 end titers. Each three-fold increase in RBD end titer reduced the odds of first-time 305 post-vaccination infection with Omicron by 21% (aOR: 0.79, 95% CI: [0.66, 0.96]). Each three-306 fold increase in S2 end titer reduced the odds of post-vaccination infection by 25% (aOR: 0.75, 307 95% CI: [0.63, 0.91]) (Table 3). Compared to the reference end titer (no antibodies detected at 308 the 1:60 dilution), estimated risk reduction was 50% at RBD and S2 end titers between 1:540 and 309 1:1620 (Fig 2). Models including AUC data as our antibody measurement had similar results. 310 Full results including estimates for all variables included in the models can be found in the 311 supplemental material (S3 and S4 Tables). 312 313 Table 3. Unadjusted and adjusted odds ratios (ORs) generated by conditional logistic 314 regression models for a nested sample of individuals with first-time post-vaccination 315 infection following third COVID-19 origin strain WA-1 monovalent mRNA vaccine dose 316 and matched controls (n=1226) and for a nested sample of individuals with reinfection and 317 matched controls, stratified by vaccination status (n=700) from the HEROES/RECOVER 318 prospective cohort of frontline workers.

319

				RI	BD	S2	
Study Sample	N	Outcome	Predictor	Unadjusted OR	Adjusted OR	Unadjusted OR	Adjusted OR
				(95% CI)	(95% CI)	(95% CI)	(95% CI)

Never Infected,	1226	Post-Vaccination	End Titer	0.82 (0.68, 0.98)*	0.79 (0.66, 0.96)*	0.74 (0.63, 0.87)*	0.75 (0.63, 0.88)*
3 doses origin strain WA-1		Omicron Infection	AUC	0.78 (0.69, 0.88)*	0.77 (0.67, 0.88)*	0.80 (0.70, 0.90)*	0.79 (0.69, 0.90)*
monovalent mRNA vaccine <sup>a</sup>							
Prior Infection,	314	Reinfection	End Titer	0.77 (0.66, 0.91)*	0.77 (0.65, 0.92)*	0.80 (0.63, 1.01)	0.82 (0.64, 1.04)
Unvaccinated <sup>b</sup>			AUC	0.63 (0.46, 0.88)*	0.64 (0.44, 0.93)*	0.75 (0.59, 0.96)*	0.72 (0.54, 0.94)*
Prior Infection +	190	Reinfection	End Titer	0.75 (0.47, 1.21)	0.73 (0.44, 1.21)	0.89 (0.59, 1.35)	0.84 (0.54, 1.30)
2 doses origin strain WA-1			AUC	0.86 (0.56, 1.32)	0.91 (0.55, 1.50)	0.83 (0.58, 1.19)	0.91 (0.61, 1.34)
monovalent mRNA vaccine <sup>c</sup>							
Prior Infection +	196	Reinfection	End Titer	0.39 (0.20, 0.77)*	0.42 (0.22, 0.84)*	0.41 (0.22, 0.79)*	0.41 (0.21, 0.80)*
3 doses origin strain WA-1			AUC	0.45 (0.25, 0.81)*	0.51 (0.28, 0.94)*	0.51 (0.32, 0.83)*	0.56 (0.34, 0.92)*
monovalent mRNA vaccine <sup>d</sup>							

320

321 Abbreviations: OR: odds ratio; CI: confidence interval

322 Adjusted models include age, gender, presence of at least 1 chronic condition, weekly exposure to individuals infected with SARS-CoV-2,

323 personal protective equipment (PPE) usage at work and in the community.

324 Odds ratio represents odds of being a case for each 3-fold increase in end titer.

325 Cases were defined as individuals who became infected with Omicron after receiving three origin strain WA-1 monovalent COVID-19 vaccine

326 doses and no prior infections. Cases and controls were matched on number of days between blood draw and third vaccine dose, and study site.

327 bCases were defined as individuals who became reinfected with SARS-CoV-2 while unvaccinated. Both cases and controls were unvaccinated at

the time of their blood draw.

329 Cases were defined as individuals who became reinfected with SARS-CoV-2. Both cases and controls were unvaccinated at time of initial

330 infection, then received 2 doses of an origin strain WA-1 monovalent COVID-19 vaccine prior to any potential reinfection. Blood draw for both

cases and controls occurred after the 2nd dose.

332 dCases were defined as individuals who became reinfected with SARS-CoV-2. Both cases and controls were unvaccinated at time of initial

333 infection, then received 3 doses of an origin strain WA-1 monovalent COVID-19 vaccine prior to any potential reinfection. Blood draw for both

cases and controls occurred after the 3rd dose.

335 \*Statistically significant at alpha = 0.05

336

337 Fig 3. Adjusted relative risk reduction for first-time post-vaccination infection with

- 338 Omicron following a third dose of an origin strain WA-1 monovalent mRNA COVID-19
- 339 vaccine among frontline workers in the HEROES/RECOVER cohort with 95% confidence
- 340 intervals using an end titer level of 1:60 as the reference.

Samples where antibody response was still detected at the final dilution were imputed to 1:9720.
The estimated percent reduction was 50% near the 1:1620 dilution for RBD and between the
1:540 and 1:1620 dilution for S2.

344

#### 345 **Reinfection**

346 The sample set of 350 cases of reinfection and 350 matched controls included 157 pairs 347 who were unvaccinated, 95 pairs who had completed the primary series of two doses of COVID-348 19 origin strain WA-1 monovalent mRNA vaccine, and 98 pairs who had received 3 doses. In the 349 general HEROES/RECOVER cohort, the incidence of reinfections with the Omicron variant for 350 individuals who were unvaccinated, had 2 doses, and had 3 doses was 0.98, 0.71, and 0.71 per 351 1000 person-days, respectively. Overall, most participants were female (57%), white and non-352 Hispanic (68%), and had no chronic conditions (65%). Most cases and controls were first 353 infected with the origin strain WA-1 strain of SARS-CoV-2 (76%) (Table 1). Although cases and 354 controls were matched on the interval between the most recent immune conferring event (first 355 infection or vaccination) and the date of their blood draw, there was a nominal but statistically 356 significant difference (113 days for cases and 129 days for controls, p < 0.001) (Table 1) due to 357 being matched on intervals as described previously in the methods. Compared to cases, controls had a higher percentage of individuals at the highest imputed end titer level (1:9720) (RBD: 358 359 40.0% vs. 34.0%; S2: 37.4% vs. 34.9%) and had higher mean AUC values for RBD (0.0098 vs. 360 0.0088) and S2 (0.0110 vs. 0.0102) (Table 2 and S2 Fig). Demographic information stratified by 361 vaccination status can be found in the supplemental material (S1 and S2 Tables). 362 In unadjusted and adjusted conditional logistic regression models stratified by 363 vaccination status, the strongest protective effects of humoral antibody levels against reinfection

364	were noted among those with a third dose of vaccine; among those unvaccinated or with two
365	doses of vaccine, protective effects of antibody levels were suggested but statistical significance
366	was not consistent across all groups. Likelihood ratio tests assessing the interaction between
367	vaccination status and antibody titers had p-values of 0.12 and 0.07 for RBD and S2 end titer,
368	respectively, indicating evidence of a potential difference by vaccination status. For
369	unvaccinated individuals, each three-fold increase in RBD and S2 end titer value was estimated
370	to reduce the odds of reinfection by 23% and 18%, respectively, although the estimate for S2 was
371	not statistically significant (RBD aOR: 0.77, 95% CI: [0.65, 0.92]; S2 aOR: 0.82, 95% CI: [0.64,
372	1.04]) (Table 3). For unvaccinated individuals, compared to an RBD end titer value of 1:60, risk
373	was reduced by 50% between end titer values of 1:540 and 1:1620, respectively (Fig 3).
374	
375	Fig 4. Adjusted relative risk reduction in reinfection with Omicron among frontline
375 376	Fig 4. Adjusted relative risk reduction in reinfection with Omicron among frontline workers in the HEROES/RECOVER cohort infection by humoral antibody titer levels with
375 376 377	Fig 4. Adjusted relative risk reduction in reinfection with Omicron among frontline workers in the HEROES/RECOVER cohort infection by humoral antibody titer levels with 95% confidence intervals <sup>a</sup> using end titer level of 1:60 as the reference and stratified by
<ul><li>375</li><li>376</li><li>377</li><li>378</li></ul>	Fig 4. Adjusted relative risk reduction in reinfection with Omicron among frontline workers in the HEROES/RECOVER cohort infection by humoral antibody titer levels with 95% confidence intervals <sup>a</sup> using end titer level of 1:60 as the reference and stratified by number of origin strain WA-1 monovalent mRNA COVID-19 vaccine doses.
<ul> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> </ul>	Fig 4. Adjusted relative risk reduction in reinfection with Omicron among frontlineworkers in the HEROES/RECOVER cohort infection by humoral antibody titer levels with95% confidence intervals <sup>a</sup> using end titer level of 1:60 as the reference and stratified bynumber of origin strain WA-1 monovalent mRNA COVID-19 vaccine doses.Samples where antibody response was still detected at the final dilution were imputed to 1:9720.
<ul> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> </ul>	Fig 4. Adjusted relative risk reduction in reinfection with Omicron among frontlineworkers in the HEROES/RECOVER cohort infection by humoral antibody titer levels with95% confidence intervals <sup>a</sup> using end titer level of 1:60 as the reference and stratified bynumber of origin strain WA-1 monovalent mRNA COVID-19 vaccine doses.Samples where antibody response was still detected at the final dilution were imputed to 1:9720.Among unvaccinated individuals, the estimated percent reduction was 50% between the 1:540
<ul> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> <li>381</li> </ul>	Fig 4. Adjusted relative risk reduction in reinfection with Omicron among frontlineworkers in the HEROES/RECOVER cohort infection by humoral antibody titer levels with95% confidence intervals <sup>a</sup> using end titer level of 1:60 as the reference and stratified bynumber of origin strain WA-1 monovalent mRNA COVID-19 vaccine doses.Samples where antibody response was still detected at the final dilution were imputed to 1:9720.Among unvaccinated individuals, the estimated percent reduction was 50% between the 1:540and 1:1620 dilution for RBD. Among individuals with 3 prior COVID-19 vaccine doses, the
<ul> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> <li>381</li> <li>382</li> </ul>	Fig 4. Adjusted relative risk reduction in reinfection with Omicron among frontlineworkers in the HEROES/RECOVER cohort infection by humoral antibody titer levels with95% confidence intervals <sup>a</sup> using end titer level of 1:60 as the reference and stratified bynumber of origin strain WA-1 monovalent mRNA COVID-19 vaccine doses.Samples where antibody response was still detected at the final dilution were imputed to 1:9720.Among unvaccinated individuals, the estimated percent reduction was 50% between the 1:540and 1:1620 dilution for RBD. Among individuals with 3 prior COVID-19 vaccine doses, theestimated percent reduction was 50% between the 1:60 and 1:180 dilution.
<ul> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> <li>381</li> <li>382</li> <li>383</li> </ul>	Fig 4. Adjusted relative risk reduction in reinfection with Omicron among frontlineworkers in the HEROES/RECOVER cohort infection by humoral antibody titer levels with95% confidence intervals <sup>a</sup> using end titer level of 1:60 as the reference and stratified bynumber of origin strain WA-1 monovalent mRNA COVID-19 vaccine doses.Samples where antibody response was still detected at the final dilution were imputed to 1:9720.Among unvaccinated individuals, the estimated percent reduction was 50% between the 1:540and 1:1620 dilution for RBD. Among individuals with 3 prior COVID-19 vaccine doses, theestimated percent reduction was 50% between the 1:60 and 1:180 dilution.°95% confidence interval only available for models with a statistically significant coefficient for
<ul> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> <li>381</li> <li>382</li> <li>383</li> <li>384</li> </ul>	Fig 4. Adjusted relative risk reduction in reinfection with Omicron among frontlineworkers in the HEROES/RECOVER cohort infection by humoral antibody titer levels with95% confidence intervals <sup>a</sup> using end titer level of 1:60 as the reference and stratified bynumber of origin strain WA-1 monovalent mRNA COVID-19 vaccine doses.Samples where antibody response was still detected at the final dilution were imputed to 1:9720.Among unvaccinated individuals, the estimated percent reduction was 50% between the 1:540and 1:1620 dilution for RBD. Among individuals with 3 prior COVID-19 vaccine doses, theestimated percent reduction was 50% between the 1:60 and 1:180 dilution.°95% confidence interval only available for models with a statistically significant coefficient forend titer when alpha is 0.05.

386	For individuals vaccinated with two doses of vaccine following their first infection, each
387	three-fold increase in RBD and S2 end titer value was estimated to reduce the odds of reinfection
388	by 27% and 16%, respectively; however, both of these estimates were not statistically significant
389	(RBD aOR: 0.73, 95% CI: [0.44, 1.21]; S2 aOR: 0.84, 95% CI: [0.54, 1.30]) (Tables 3).
390	For individuals with three origin strain WA-1 monovalent COVID-19 mRNA vaccine
391	doses following their first infection, each three-fold increase in RBD and S2 end titer values
392	reduced the estimated odds of reinfection by 58% and 59%, respectively (RBD aOR: 0.42, 95%
393	CI: [0.22, 0.84]; S2 aOR: 0.41, 95% CI: [0.21, 0.80]) (Table 3). Compared to RBD and S2 end
394	titer values of 1:60, risk was reduced by 50% at end titer values between 1:60 and 1:180 for each
395	(Fig 3). Models including AUC data as our antibody measurement had similar results. Full
396	results including estimates for all variables included in the models can be found in the
397	supplemental material (S5 and S6 Tables).

### 398 **Discussion**

399 In this analysis of frontline workers from eight US locations, higher levels of RBD 400 antibodies were associated with protection against first-time post-vaccination infection and 401 reinfection with Omicron. The risk of first-time post-vaccination infection with Omicron 402 following a third dose of monovalent mRNA vaccine was reduced by 21% for each three-fold 403 increase in RBD end titer, with estimated 50% risk reductions achieved at end titers between 404 1:540 and 1:1620. The magnitude of risk reduction against reinfection depended on vaccination 405 status, with some evidence that this difference was significant based on p-values from likelihood 406 ratio tests of 0.12 and 0.07 for RBD and S2 end titers, respectively. For unvaccinated individuals 407 with a prior infection, a 3-fold increase in RBD reduced reinfection risk by 23%. There were no 408 statistically significant protective effects for those with a previous infection and two origin strain

WA-1 monovalent COVID-19 mRNA doses following infection. However, for individuals with
three vaccine doses following their first infection, a 3-fold increase in RBD end titer value
reduced reinfection risk by 58%, with estimated 50% reductions in SARS-CoV-2 reinfection risk
occurring at end titers between 1:60 and 1:180. The protective effect of higher antibody levels
was robust in those with a third dose of vaccine, regardless of previous infection status.
However, those with previous infection showed a 50% reduction in risk at lower titers compared
to those who were not previously infected, though we could not test this difference for statistical

416 significance [4].

430

417 These findings build on previous literature reporting correlates of protection against

418 SARS-CoV-2 infection in different populations and at different points during the pandemic.

419 Early vaccine efficacy trials in the US found higher post-vaccination end titers in vaccine

420 recipients to be associated with higher vaccine efficacy [2]. Similarly, early SARS-CoV-2 post-

421 vaccination infections associated with the Alpha variant among healthcare workers in Israel were
422 associated with lower neutralizing antibody titers in the peri-infection period [20]. In a household

423 transmission study of Delta variant infections, both quantitative ELISA and neutralizing antibody

titers were protective against secondary Delta infection, with titers over 1:1000 providing an

425 immunologic threshold for protection [21]. Other studies examining the role of antibody levels

426 and functional protection against Omicron infection have shown mixed results [22, 23]. One

427 potential explanation as to why serologic antibody levels could be less protective against

428 Omicron infection is that, compared to previous variants, Omicron is relatively confined to the 429 upper respiratory tract and therefore higher mucosal antibody threshold levels could be required

apper respiratory state and incretore ingher material antibody inconord to tel to require

to prevent infection [24]. This provides a potential explanation for why 50% risk reductions in

this study were achieved at higher end titer levels for individuals with three vaccines and no

432 previous infection compared to lower titer levels for those with a previous infection followed by 433 three vaccine doses. These findings in combination with previous studies underscore the 434 importance of considering both vaccination and infection history, as well as number of immune 435 conferring events, when estimating functional protection against SARS-CoV-2 infection [25-29]. 436 This study is subject to several limitations. First, because the semi-quantitative ELISA 437 assessed only five dilutions, and many individuals had an immune response at the highest 438 dilution, ability to differentiate individuals with a response above the highest dilution is limited. 439 Additionally, treating this outcome as a continuous measure assumes linearity in the log-odds for 440 each 3-fold increase in titer level. However, our models with AUC as the outcome, which is less 441 sensitive to any potential ceiling effects, had similar results to the models using end titer data (S3 442 and S5 Tables), which helps confirm our end titer results [30]. Second, neutralizing antibodies 443 are typically the gold standard in assessing correlates of protection, and for these analyses, a 444 surrogate measure of semi-quantitative ELISA was used. However, antibodies measured via the 445 semi-quantitative ELISA assay used in this study are known to correlate closely with 446 neutralization of live SARS-CoV-2 virus [17, 31]. We only ran ELISAs against the origin strain 447 WA-1 strain of SARS-CoV-2, meaning that specific antibodies against the Omicron variant may 448 differ from the results found here. Third, although the reinfection study data were matched on the 449 interval between the most recent immune conferring event (first infection or vaccination) and 450 blood draw, the residual differences in those times between the cases and controls may have 451 provided some residual confounding. Additionally, differences in mean time intervals between 452 the two analytic samples, as well as waning antibodies for samples that were further away from 453 the previous immune-conferring event, may affect direct comparisons in results. Fourth, the 454 HEROES/RECOVER cohort consists of frontline workers, and therefore these findings may not

455 be generalizable beyond relatively healthy populations and populations with regular exposure to 456 SARS-CoV-2. Due to this healthy population, we were unable to evaluate severe disease as an 457 outcome. Finally, participants are subject to misclassification when determining eligibility for 458 the two case-control cohorts and case or control status. Since we were limited to using RBD and 459 S2 when determining prior infection at baseline, we solely relied on self-reported data for 460 individuals who were vaccinated at baseline, and misclassification could occur if any of these 461 participants incorrectly reported or failed to report a pre-study infection. Strengths of this study 462 include its large sample size, its representativeness of Hispanic/Latino populations consistent 463 with US demographic trends, and weekly active surveillance for infections regardless of 464 symptoms.

465 In a population of frontline workers with diverse immunological histories, those with 466 higher antibody levels had consistently lower risk of Omicron infection. Antibody correlates of 467 protection against first-time post-vaccination infection and reinfection could be estimated for 468 individuals who had received a third dose of a vaccine: odds of first-time post-vaccination 469 infection were reduced by 21% for each 3-fold increase in RBD end titers, while the odds of 470 reinfection were reduced by 58% for each 3-fold increase in RBD end titers for individuals with 471 three mRNA vaccine doses following their first infection. Although we were able to estimate 472 these reductions separately for each group, we were unable to statistically compare these two 473 cohorts. Findings underscore the importance of immunologic heterogeneity, and contribution of 474 hybrid immunity, when estimating functional protection against SARS-CoV-2 infection. Future 475 studies could assess the Omicron-specific correlates of protection using surrogate or authentic 476 neutralization assays, which could enable more credible interpretations about functional

477 protection against currently circulating strains, especially with the continued updates to COVID-478 19 vaccines [32].

479

### 480 Acknowledgments

481 CDC: Eduardo Azziz-Baumgartner, Melissa L. Arvay, William Brannen, Stephanie Bialek,

482 Allison Ciesla, Alicia M. Fry, Aron Hall, Adam MacNeil, Clifford McDonald, Sue Reynolds,

483 Robert Slaughter, Matthew J. Stuckey, Rose Wang, Ryan Wiegand; Abt Associates: Steve

484 Pickett, Rekha Balachandran, Kim Groover, Deanna Fleary, Peenaz Mistry; BSWH: Kayan

485 Dunnigan, Nicole Calhoun, Leah Odame-Bamfo, Clare Mathenge, Michael E. Smith,

486 Kempapura Murthy, Tnelda Zunie, Eric Hoffman, Martha Zayed, Ashley Graves, Joel Blais,

487 Jason Ettlinger, Sharla Russell, Natalie Settele, Tiya Searcy, Rupande Patel, Elisa Priest, Jennifer

488 Thomas, Muralidhar Jatla, Madhava Beeram, Javed Butler, Alejandro Arroliga; KPNW: Holly

489 Groom, Yolanda Prado, Daniel Sapp, Mi Lee, Chris Eddy, Matt Hornbrook, Donna Eubanks,

490 Danielle Millay, Dorothy Kurdyla, Kristin Bialobok, Ambrosia Bass, Kristi Bays, Kimberly

491 Berame, Cathleen Bourdoin, Rashyra Brent, Carlea Buslach, Lantoria Davis, Stephen Fortmann,

492 Jennifer Gluth, Kenni Graham, Tarika Holness, Kelley Jewell, Enedina Luis, Abreeanah

493 Magdaleno, DeShaun Martin, Joyce Smith-McGee, Martha Perley, Sam Peterson, Aaron Peipert,

494 Krystil Phillips, Joanna Price, Ana Reyes, Sperry Robinson, Katrina Schell, Emily Schield,

495 Natosha Shirley, Anna Shivinsky, Valencia Smith, Britta Torgrimson-Ojerio, Brooke

496 Wainwright, Shawn Westaway; Marshfield Clinic Research Laboratory: Saydee Benz, Adam

497 Bissonnette, Krystal Boese, Emily Botten, Jarod Boyer, Michaela Braun, Julianne Carlson, Caleb

498 Cravillion, Amber Donnerbauer, Tim Dziedzic, Joe Eddy, Heather Edgren, Alex Ermeling,

499 Kelsey Ewert, Connie Fehrenbach, Rachel Fernandez, Wayne Frome, Sherri Guzinski, Mitch

500	Hertel, Garrett Heuer, Erin Higdon, Cressa Huotari, Lynn Ivacic, Lee Jepsen, Steve Kaiser,
501	Bailey Keffer, Tammy Koepel, Sarah Kohn, Alaura Lemieux, Carrie Marcis, Megan Maronde,
502	Isaac McCready, Nidhi Mehta, Dan Miesbauer, Collin Nikolai, Brooke Olson, Jeremy Olstadt,
503	Lisa Ott, Cory Pike, Nicole Price, Chris Reardon, Alex Slenczka, Elisha Stefanski, Lydia
504	Sterzinger, Kendra Stoltz, Melissa Strupp, Lyndsay Watkins, Roxann Weigel, Ben
505	Zimmerman; University of Miami: Damena Gallimore-Wilson, Roger Noriega, Cynthia Beaver,
506	Alexandra Cruz, Annabel Reyes, Brigitte Madan, Addison Testoff, John Jones; St. Luke's:
507	Jessica Lundgren, Karley Respet, Angela Hunt, Jennifer Viergutz, Daniel Stafki, Mary
508	Robinson, Elizabeth Kaplan, Jill Dolezilek, Leiah Hoffman, Tyna O'Connor, Abbigail Hagen,
509	Catherine Diluzio, Samantha Kendrick, Marilyn J. Odean; University of Arizona: Ariyah
510	Armstrong, Nora Baccam, Zoe Baccam, Tatum Butcher, Shelby Capell, Andrea Carmona,
511	Karysa Carson, Alissa Coleman, Hannah Cowling, Carly Deal, Kiara Earley, Sophie Evans, Julia
512	Fisher, Ashlyn Flangos, Joe K. Gerald, Lynn Gerald, Anna Giudici, Erika Goebert, Taylor
513	Graham, Sofia Grijalva, Hanna Hanson, Olivia Healy, Chloe Hendrix, Katherine Herder,
514	Adrianna Hernandez, Raven Hilyard, Rezwana Islam, Krystal S. Jovel, Caroline Klinck, Karl
515	Krupp, Karla Ledezma, Sally Littau, Amelia Lobos, Ashley Lowe, Jeremy Makar, Natalya
516	Mayhew, Kristisha Mevises, Flavia Nakayima Miiro, Cierra Morris, Sarah Murray,
517	Janko Nikolich-Žugich, Assumpta Nsengiyunva, Kennedy Obrien, Mya Pena, Riley Perlman,
518	Celia Pikowski, Ferris A. Ramadan, Patrick Rivers, Jen Scott, Priyanka Sharma, Alison Slocum,
519	Saskia Smidt, Lili Steffen, Jayla Sowell, Danielle Stea, Xiaoxiao Sun, Nicholas Tang, Gianna
520	Taylor, Ta'Nya Tomas, Heena Timsina, Italia Trejo, April Yingst; University of Utah: Rachel T.
521	Brown, Matthew Bruner, Riley Campbell, Aniysah Colston, Brianna Cottam, Chapman Cox,
522	Kendal Chatard, Ben Cragun, Daniel Dawson, Anika Dsouza, Emilee Eden, Amanda Flanagan,

523	Colton Fox, Adriele Fugal, Nikki Gallacher, Michelle Gillette, Joshua Griffin, Christian
524	Guzman, Isaac Hansen, Addie Hunsaker, Iman Ibrahim, Nada Jabbouri, Junny Jeong, Ryder
525	Jordin, Tori Joy, Michael Langston, Alexis Lowe, Katie Luong, Aurianna Martin, Gretchen
526	Maughan, Jinyi Mao, Jeanmarie Mayer, Katy McCone, Renee McEntire, Jacob McKell, Tiana
527	Miller, Max Minoughan, Naveen Naveed, Jessica Olsen, Christina Pick, Timina Powaukee,
528	Jenna Praggastis, Lily Prentice, Seon Reed, Amber Rhodes, Griffin Rost, Camie Schaefer,
529	Ashmita Shanthakumar, Madeleine Smith, Joseph Stanford, Grace Stewart, Pasha Stinson,
530	Trevor Stubbs, Marcus Stucki, Madison Tallman, Sydney Taylor, Kathy Tran, Fiona
531	Tsang, Irene Tucker, Maya Wheeler, Megan Wilson, Jesse Williams, Derrick Wong,
532	Jenna Vo, Hannah Whiting, Iris Yang, Karly Anderson, Ian Arlington, Arlyne Arteaga,
533	Braydon Black, Brock Bourdelle.
534	
535	Special thanks to the firefighters, healthcare workers, and frontline and essential workers who
536	participated in this cohort study.

537

## 538 **References**

Reynolds CJ, Gibbons JM, Pade C, Lin K-M, Sandoval DM, Pieper F, et al. Heterologous
infection and vaccination shapes immunity against SARS-CoV-2 variants. Science.

- 541 2022;375(6577):183-92.
- 542 2. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al.
- 543 Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
- 544 Science. 2022;375(6576):43-50.

545	3.	Herring MK, Romine JK, Wesley MG, Ellingson KD, Yoon SK, Caban-Martinez AJ, et			
546	al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response				
547	to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses. Clinical Infectious Diseases.				
548	2022:ciac976.				
549	4.	Gilboa M, Regev-Yochay G, Mandelboim M, Indenbaum V, Asraf K, Fluss R, et al.			
550	Durability of Immune Response After COVID-19 Booster Vaccination and Association With				
551	COVID-19 Omicron Infection. JAMA Network Open. 2022;5(9):e2231778.				
552	5.	Fu J, Shen X, Anderson M, Stec M, Petratos T, Cloherty G, et al. Correlation of Binding			
553	and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and				
554	Convalescent BNT162b2 Recipients. Vaccines. 2022;10(11):1904.				
555	6.	Spinardi JR, Srivastava A. Hybrid Immunity to SARS-CoV-2 from Infection and			
556	Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines.				
557	Biomedicines. 2023;11(2):370.				
558	7.	Koup RA, Donis RO, Gilbert PB, Li AW, Shah NA, Houchens CR. A government-led			
559	effort to identify correlates of protection for COVID-19 vaccines. Nature Medicine.				
560	2021;27(9):1493-4.				
561	8.	Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between			
562	haemagglutination-inhibiting antibody titres and clinical protection against influenza:				
563	development and application of a bayesian random-effects model. BMC Med Res Methodol.				
564	2010;	2010;10:18.			
565	9.	Nakaya HI, Hagan T, Duraisingham SS, Lee EK, Kwissa M, Rouphael N, et al. Systems			
566	Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations				
567	Revea	Reveals Shared Molecular Signatures. Immunity. 2015;43(6):1186-98.			

568 10. Ridgway JP. Lideman S. French I. Wright B. Parsons G. Diaz G.	J. et al. Odds of
---	-------------------

- 569 Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since
- 570 Booster Dose. JAMA. 2022;328(15):1559.
- 571 11. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol.
- 572 2010;17(7):1055-65.
- 573 12. Dadras O, Seyedalinaghi SA, Karimi A, Shojaei A. COVID-19 Vaccines' Protection Over
- 574 Time and the Need for Booster Doses; a Systematic Review. Archives of Academic Emergency
- 575 Medicine. 2022;10(1).
- 576 13. Nealon J, Cowling BJ. Uncertainties About the Optimal Timing of Fourth Dose of
- 577 COVID-19 Vaccines. JAMA Network Open. 2022;5(7):e2223096-e.
- 578 14. Lutrick K, Ellingson KD, Baccam Z, Rivers P, Beitel S, Parker J, et al. COVID-19
- 579 Infection, Reinfection, and Vaccine Effectiveness in Arizona Frontline and Essential Workers:
- 580 Protocol for a Longitudinal Cohort Study. JMIR Res Protoc. 2021;10(6):e28925.
- 581 15. Edwards LJ, Fowlkes AL, Wesley MG, Kuntz JL, Odean MJ, Caban-Martinez AJ, et al.
- 582 Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER):
- 583 Protocol for a Multisite Longitudinal Cohort Study. JMIR Res Protoc. 2021;10(12):e31574.
- 16. Prevention CfDCa. COVID data tracker: variant proportions 2023 [cited 2023 Aug 28].
- 585 17. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al.
- 586 Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence
- 587 Communities and Reveal Durable Humoral Immunity. Immunity. 2020;53(5):925-33.e4.
- 588 18. Ng S, Fang VJ, Ip DK, Chan KH, Leung GM, Peiris JS, et al. Estimation of the
- association between antibody titers and protection against confirmed influenza virus infection in
- 590 children. J Infect Dis. 2013;208(8):1320-4.

591	19.	Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, et al.			
592	Hemag	glutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated			
593	Influenza Vaccines in Children. The Pediatric Infectious Disease Journal. 2011;30(12):1081-5.				
594	20.	Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19			
595	Breakthrough Infections in Vaccinated Health Care Workers. New England Journal of Medicine.				
596	2021;385(16):1474-84.				
597	21.	Regev-Yochay G, Lustig Y, Joseph G, Gilboa M, Barda N, Gens I, et al. Correlates of			
598	protection against COVID-19 infection and intensity of symptomatic disease in vaccinated				
599	individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study.				
600	The La	ncet Microbe. 2023;4(5):e309-e18.			
601	22.	Asamoah-Boaheng M, Goldfarb DM, Karim ME, SF OB, Wall N, Drews SJ, et al. The			
602	Relatio	nship Between Anti-Spike SARS-CoV-2 Antibody Levels and Risk of Breakthrough			
603	COVII	D-19 Among Fully Vaccinated Adults. J Infect Dis. 2023;227(3):339-43.			
604	23.	Lee J, Park S, Kim JY, Lim SY, Chang E, Bae S, et al. No correlation of neutralizing			
605	antiboo	ly titers against the Omicron variant after a booster dose of COVID-19 vaccines with			
606	subsequent breakthrough Omicron infections among healthcare workers. Journal of Infection.				
607	2022;8	5(6):e177-e80.			
608	24.	Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2			
609	Omicro	on variant replication in human bronchus and lung ex vivo. Nature. 2022;603(7902):715-			
610	20.				
611	25.	Dimeglio C, Migueres M, Chapuy-Regaud S, Da-Silva I, Jougla I, Pradere C, et al.			
612	Compa	rative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing			

613 antibody response. Journal of Infection. 2022;85(1):e4-e6.

- 614 26. Dphil NB. Protective effectiveness of previous SARS-CoV-2 infection and hybrid
- 615 immunity against the omicron variant and severe disease: a systematic review and meta-
- 616 regression. 2023;23.
- 617 27. de Gier B, Huiberts AJ, Hoeve CE, den Hartog G, van Werkhoven H, van Binnendijk R,
- et al. Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2
- 619 infection and relation with serology. Nature Communications. 2023;14(1):4793.
- 620 28. Wei J, Matthews PC, Stoesser N, Newton JN, Diamond I, Studley R, et al. Protection
- 621 against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough
- 622 infection in the UK. Nature Communications. 2023;14(1):2799.
- 623 29. Wei J, Pouwels KB, Stoesser N, Matthews PC, Diamond I, Studley R, et al. Antibody
- responses and correlates of protection in the general population after two doses of the ChAdOx1
- 625 or BNT162b2 vaccines. Nature Medicine. 2022;28(5):1072-82.
- 626 30. Yu X, Gilbert PB, Hioe CE, Zolla-Pazner S, Self SG. Statistical approaches to analyzing
- HIV-1 neutralizing antibody assay data. Stat Biopharm Res. 2012;4(1):1-13.
- 628 31. Stone M, Grebe E, Sulaeman H, Di Germanio C, Dave H, Kelly K, et al. Evaluation of
- 629 Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance
- and Related Applications. Emerg Infect Dis. 2022;28(3):672-83.
- 631 32. Benkeser D, Montefiori DC, McDermott AB, Fong Y, Janes HE, Deng W, et al.
- 632 Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-
- 633 1273 vaccine efficacy trial. Science Translational Medicine. 2023;15(692):eade9078.

634

### 635 Supporting information

636

#### 637 S1 Table. Demographic information for reinfection correlates of protection nested case-

#### 638 control cohort from AZHEROES/RECOVER, stratified by vaccination status.

- <sup>a</sup>All vaccine doses are monovalent origin strain WA-1 mRNA vaccines.
- <sup>b</sup>Other essential workers include occupation sectors with potentially high exposures to SARS-
- 641 CoV-2 such as education, agriculture, public transportation services, waste collection, delivery,
- 642 utilities, community-based services, childcare, and others.
- 643 Chronic conditions include asthma, chronic lung disease, cancer, diabetes, heart disease,
- 644 hypertension, immunosuppression, kidney disease, liver disease, neurologic or neuromuscular
- 645 disease or disorder, and autoimmune disease.
- <sup>646</sup> <sup>d</sup>Participants are asked "Are you currently taking prednisone or other ongoing steroid
- 647 medications (excluding inhaled steroids and one-time injections) or any other medications that
- 648 may suppress your body's ability to fight infection?".
- <sup>649</sup> <sup>e</sup>ICE (immune conferring event) is the third vaccine dose for the first-time post-vaccination
- 650 infection with Omicron cohort and the 3 dose strata within the reinfection cohort, the second
- vaccine dose for the 2 dose strata within the reinfection cohort, and the initial SARS-CoV-2
- 652 infection for the unvaccinated strata within the reinfection cohort.
- <sup>653</sup> <sup>f</sup>Exposure to individuals infected with SARS-CoV-2.
- <sup>654</sup> <sup>g</sup>Reported personal protective equipment (PPE) adherence at work was defined as the percentage
- of time in which an individual uses the PPE recommended by their employer when in direct
- 656 contact with people.

657

- 658 S2 Table. Count and descriptive statistics of quantitative antibody results for reinfection
- 659 correlates of protection cohort from AZHEROES/RECOVER, stratified by vaccination
- 660 status.
- 661
- 662 S3 Table. Results from conditional logistic regression model with RBD and S2 AUC values
- 663 for first-time post-vaccination infection with Omicron following third COVID-19 origin
- 664 strain WA-1 monovalent mRNA vaccine dose correlates of protection cohort from
- 665 AZHEROES/RECOVER (n=1226).
- 666 Abbreviations: OR: odds ratio; CI: confidence interval.
- 667 Odds ratio represents odds of being a case for each standard deviation increase in AUC.
- 668 Cases were defined as individuals who became infected with Omicron after receiving three
- origin strain WA-1 monovalent COVID-19 vaccine doses and no prior infections. Cases and
- 670 controls were matched on number of days between blood draw and third vaccine dose, and study
- 671 site.
- 672 \*Statistically significant at alpha = 0.05.
- 673
- 674 S4 Table. Results from conditional logistic regression model with RBD and S2 AUC values
- 675 for the reinfection correlates of protection cohort from HEROES/RECOVER.
- 676 Abbreviations: OR: odds ratio; CI: confidence interval.
- 677 Odds ratio represents odds of being a case for each standard deviation increase in AUC.
- <sup>678</sup> <sup>a</sup>Cases were defined as individuals who became reinfected with SARS-CoV-2 while
- 679 unvaccinated. Both cases and controls were unvaccinated at the time of their blood draw.

- <sup>680</sup> <sup>b</sup>Cases were defined as individuals who became reinfected with SARS-CoV-2. Both cases and
- 681 controls were unvaccinated at time of initial infection, then received 2 doses of an origin strain
- 682 WA-1 monovalent COVID-19 vaccine prior to any potential reinfection. Blood draw for both
- 683 cases and controls occurred after the 2nd dose.
- <sup>684</sup> <sup>c</sup>Cases were defined as individuals who became reinfected with SARS-CoV-2. Both cases and
- 685 controls were unvaccinated at time of initial infection, then received 3 doses of an origin strain
- 686 WA-1 monovalent COVID-19 vaccine prior to any potential reinfection. Blood draw for both
- 687 cases and controls occurred after the 3rd dose.
- <sup>d</sup>At least one chronic condition versus no chronic conditions.
- 689 <sup>e</sup>Above cohort mean versus below cohort mean.
- 690 \*Statistically significant at alpha = 0.05.
- 691
- 692 S5 Table. Unadjusted and adjusted odds ratios (ORs) generated by conditional logistic
- 693 regression models for a nested sample of individuals with first-time post-vaccination
- 694 infection with Omicron following third COVID-19 origin strain WA-1 monovalent mRNA
- 695 vaccine dose and matched controls from the HEROES/RECOVER prospective cohort of
- 696 frontline workers (n=1226).
- 697 Abbreviations: OR: odds ratio; CI: confidence interval.
- 698 Odds ratio represents odds of being a case for each 3-fold increase in end titer. Cases were
- 699 defined as individuals who became infected with Omicron after receiving three COVID-19
- vaccine doses. Cases and controls were matched on number of days between blood draw and
- 701 third vaccine dose, and study site.
- <sup>a</sup>At least one chronic condition versus no chronic conditions

- <sup>703</sup> <sup>b</sup>Above cohort mean versus below cohort mean
- \*Statistically significant at alpha = 0.05
- 705
- 706 Table S6. Unadjusted and adjusted odds ratios (ORs) generated by conditional logistic
- regression models for a nested sample of individuals with reinfection and matched controls,
- 708 stratified by vaccination status, from the HEROES/RECOVER prospective cohort of
- 709 frontline workers (n=740).
- 710 Abbreviations: OR: odds ratio; CI: confidence interval.
- 711 Odds ratio represents odds of being a case for each 3-fold increase in end titer.
- 712 <sup>a</sup>Cases were defined as individuals who became reinfected with SARS-CoV-2 while
- 713 unvaccinated. Both cases and controls were unvaccinated at the time of their blood draw.
- <sup>714</sup> <sup>b</sup>Cases were defined as individuals who became reinfected with SARS-CoV-2. Both cases and
- controls were unvaccinated at time of initial infection, then received 2 doses of an origin strain
- 716 WA-1 monovalent COVID-19 vaccine prior to any potential reinfection. Blood draw for both
- 717 cases and controls occurred after the 2nd dose.
- 718 Cases were defined as individuals who became reinfected with SARS-CoV-2. Both cases and
- controls were unvaccinated at time of initial infection, then received 3 doses of an origin strain
- 720 WA-1 monovalent COVID-19 vaccine prior to any potential reinfection. Blood draw for both
- cases and controls occurred after the 3rd dose.
- <sup>722</sup> <sup>d</sup>At least one chronic condition versus no chronic conditions.
- <sup>e</sup>Above cohort mean versus below cohort mean.
- \*Statistically significant at alpha = 0.05.
- 725

- 726 S1 Fig. Comparison of RBD (panel A) and S2 (panel B) AUC values between cases and
- 727 controls in first-time post-vaccination infection with Omicron nested case-control cohort,
- 728 with difference in means evaluated by paired t-test.
- 729
- 730 S2 Fig. Comparison of mean RBD (panel A) and S2 (panel B) AUC values between cases
- and controls in reinfection Omicron infection nested case-control cohort, stratified by
- 732 number of origin strain WA-1 monovalent mRNA COVID-19 vaccine doses.

733

- 734 S3 Fig. Flowchart for determining qualitative antibody result using RBD and S2 optical
- 735 density values.
- 736
- 737 S4 Fig. Flowchart for determining pre-enrollment infections in the HEROES-RECOVER
- 738 cohort.













Fig3



Fig4